The results demonstrated that the 25mg daily pill delivered clinically meaningful weight loss: Average weight loss of 13.6-16.6% compared to 2.2-2.7% with placebo 76% of participants achieved at least 5% weight loss versus 31% on placebo Over 30% achieved 20% or greater weight loss Significant improvements in blood pressure, cholesterol, and inflammatory markers These results are comparable to what weve seen with injectable Wegovy, which typically produces 12-15% weight loss
As GLP-1s continue to expand into other diseases, Worldwide continues to work cross-functionally across indications, providing personalized solutions to each study
Disclaimer References Wilding JPH, Batterham RL, Calanna S, et al
After a successful advocacy effort, this practice was recognized as discriminatory and plans were forbidden from doing this
Based on similarities in their amino acid sequence, peptide agonists are mainly divided into GLP-1 and derivatives and exendin-4 and derivatives
The mechanism by which GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists cause nausea and vomiting is multifactorial and directly related to their pharmacological action
